EXACT Therapeutics announces appointment of Dr Amir Snapir as Chief Medical Officer
OSLO/LONDON, 16 September 2022: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced the appointment of Dr Amir Snapir as Chief Medical Officer (CMO), effective 21 September 2022.
“We are delighted to welcome Amir to EXACT-Tx as CMO. His extensive experience in clinical development and thorough understanding of the regulatory and clinical framework for drug-device combinations will be pivotal for our further development of ACT®.”, said Dr Per Walday, CEO of EXACT-Tx. “We continue to build a strong organisation with clinical and regulatory expertise for excellence in development strategy and execution. We are very happy to have Amir in this critical leadership role for the future development of ACT®”.
Dr Snapir has a PhD from the University of Turku, Finland and an MD from the University of Tel Aviv, Israel. He has extensive experience in global clinical development of novel therapeutics, from early clinical translation to marketing authorisation, combined with extensive international regulatory experience. Dr Snapir also has years of experience in business collaborations, alliances and product co-developments. Dr Snapir comes from the position as CMO of PCI Biotech where he was responsible for the clinical development of drug-device combination product candidates. From 2007 to 2020 he held various positions at Orion Pharma, Espoo, Finland, spanning from leader of clinical pharmacogenomics to clinical development leader in Oncology. Dr Snapir is the author of numerous scientific publications.
ENDS
For more information, please contact:
Dr Per Walday
Chief Executive Officer
EXACT-Tx
Email: per.walday@exact-tx.com
About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases. www.exact-tx.com
About ACT®
• ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
• ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
• Initial focus of the Company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.
Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.